Tuberculosis (TB)

Policy statements

TB diagnostics and laboratory strengthening

The landscape of TB diagnostics continues to evolve, with new technologies at various stages in the product development pipeline. WHO follows a systematic process for development of policy recommendations, involving synthesis of the available data through systematic reviews, assessment of the evidence by a Guideline Development Group using the GRADE approach, and development of policy guidance for dissemination to Member States and other stake holders.


Next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex


Drug susceptibility testing of medicines used in the treatment of tuberculosis


Critical concentrations for drug-susceptibility testing


Xpert MTB/RIF Ultra


The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin


The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis


The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs


Framework for implementing TB diagnostics


LF-LAM assay


Xpert MTB/RIF


Framework for indicators and targets for laboratory strengthening under the End TB Strategy


Biosafety


Microscopy


Culture and drug susceptibility testing (DST)


Interferon-gamma release assays (IGRAs)


Commercial serodiagnostic tests


Organization and management


Definitions and reporting